Divi’s Laboratories (DIVISLAB) Q1 25/26 earnings summary

Executive summary

• Maintained a robust position in generics despite global pricing pressures, supported by strong backward integration and long-term customer partnerships.

• Unit 3 facility in Kakinada became operational, enhancing self-sufficiency and supporting backward integration.

• Custom synthesis remains a core growth engine, with a healthy pipeline of RFPs and projects expected to commercialize in 12–24 months.

• Advanced capabilities in flow chemistry, biocatalysis, and green chemistry are differentiating factors, with new peptide synthesis capacity attracting major pharma interest.

• Consolidated total income for Q1 FY2025-26 reached ₹2,529 crores, up from ₹2,197 crores year-over-year.

Financial highlights

• Consolidated total income for Q1 FY26 was INR 2,529 crore, up from INR 2,197 crore year-over-year.

• Profit before tax rose to INR 733 crore from INR 604 crore year-over-year; profit after tax increased to INR 545 crore from INR 430 crore.

• Standalone total income was INR 2,476 crore, with profit before tax at INR 747 crore and profit after tax at INR 567 crore.

• Exports accounted for 88% of revenue, with Europe and the U.S. contributing 58% and 14%, respectively.

• Forex gain of INR 39 crore versus a loss of INR 1 crore last year; constant currency growth at 14%.

Outlook and guidance

• Estimated total capital expenditure for FY26 is INR 2,000 crore, focused on strategic projects, capacity expansion, and technology upgrades.

• Three major CapEx programs underway, backed by long-term supply commitments.

• Several custom synthesis and peptide projects expected to transition to commercial scale in the next 12–24 months.

• The company continues to focus on its core business of Active Pharmaceutical Ingredients, Intermediates, and Nutraceutical Ingredients, with no indication of discontinued operations.